Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 5
Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study
Panelists discuss how the approval of tafasitamab + lenalidomide and rituximab (R2) in the second-line (2L) setting might influence decision-making in the first-line (1L) or third line–plus (3L+) treatment settings and share their thoughts on the inMIND study, highlighting key data points and the impact of tafasitamab + R2 on clinical practice.
Video Player is loading.
Video content above is prompted by the following:
- How might the approval of tafasitamab + R2 in the 2L setting alter or impact your decision-making process in the 1L or 3L+ treatment settings?
- Feel free to share your thoughts on any differences and/or similarities in your impressions of the inMIND study and how tafasitamab + R2 might impact your clinical practice. What key highlights or data points stand out to you?
Related Content:
